News & Updates

Age does not affect palbociclib dose reduction, discontinuation in breast cancer patients
Age does not affect palbociclib dose reduction, discontinuation in breast cancer patients
06 Jan 2023

The age of patients with advanced breast cancer appears to have no influence on the rate of palbociclib dose reductions or discontinuations secondary to neutropaenia, a study has shown.

Age does not affect palbociclib dose reduction, discontinuation in breast cancer patients
06 Jan 2023
Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
05 Jan 2023 byRoshini Claire Anthony

Young breast cancer survivors could safely temporarily stop adjuvant endocrine therapy (ET) to attempt pregnancy, according to primary results of the POSITIVE* trial presented at SABCS 2022.

Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
05 Jan 2023
5α-reductase inhibitor treatment implicated in dementia
5α-reductase inhibitor treatment implicated in dementia
05 Jan 2023

Men who are receiving treatment with 5α-reductase inhibitors (5-ARIs) are at increased risk of dementia in the immediate period after initiating treatment, a study has shown. Of note, both finasteride and dutasteride are associated with depression, but neither of them is linked to suicide.

5α-reductase inhibitor treatment implicated in dementia
05 Jan 2023
Edoxaban prevents thromboembolism in children with cardiac disease
Edoxaban prevents thromboembolism in children with cardiac disease
04 Jan 2023

Edoxaban may be used as an alternative treatment for thromboembolism (TE) prevention in children with cardiac disease showing low rates of clinically relevant bleeding and TE, suggests a study. Some of its advantages include once-daily dosing and infrequent monitoring requirement.

Edoxaban prevents thromboembolism in children with cardiac disease
04 Jan 2023